Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 956
- Registration Number
- NCT06225596
- Locations
- ๐บ๐ธ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐บ๐ธVirginia K. Crosson Cancer Center at St. Jude Medical Center, Fullerton, California, United States
๐บ๐ธUniversity of California - Irvine Medical Center, Orange, California, United States
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 200
- Registration Number
- NCT05163041
- Locations
- ๐บ๐ธ
State University of Iowa, Iowa City, Iowa, United States
๐บ๐ธColumbia University Irving Medical Center, New York, New York, United States
๐บ๐ธUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
- Conditions
- Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative NeoplasmsHormone Receptor Positive, HER2-low NeoplasmsBreast NeoplasmsNon-Small-Cell Lung NeoplasmsOvarian NeoplasmAdvanced Solid Tumor
- Interventions
- Drug: BT8009Drug: Pembrolizumab
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 329
- Registration Number
- NCT04561362
- Locations
- ๐ซ๐ท
Centre Eugene Marquis, Rennes, France
๐ซ๐ทInstitut Bergonie, Bordeaux, France
๐ซ๐ทInstitut Gustave Roussy, Villejuif, France
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
- Conditions
- Triple Negative Breast CancerUrothelial CancerOvarian CancerNon-small Cell Lung CancerAdvanced Solid Tumor Historically Known for High EphA2 ExpressionHead and Neck CancerGastric/Upper Gastrointestinal Cancer
- Interventions
- Drug: BT5528Drug: Nivolumab
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 288
- Registration Number
- NCT04180371
- Locations
- ๐บ๐ธ
Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States
๐บ๐ธCalifornia Cancer Associates for Research and Excellence, Inc., Encinitas, California, United States
๐บ๐ธUniversity of California, San Diego (UCSD) - Medical Center, La Jolla, California, United States